LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aktien・Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

Geschlossen

4.5 -0.88

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.49

Max

4.52

Schlüsselkennzahlen
By Trading Economics
Einkommen	-29K -20M
Verkäufe	701K 2M
EPS	-0.15
Gewinnspanne	-993.186
Angestellte	69
EBITDA	-2.5M -22M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+129.65% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-13M 620M
Vorheriger Eröffnungskurs	5.38
Vorheriger Schlusskurs	4.5

Aclaris Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Mai 2026, 08:24 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25. Mai 2026, 21:22 UTC

Ergebnisse

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25. Mai 2026, 20:50 UTC

Market Talk

Ergebnisse

Basic Materials Roundup: Market Talk

25. Mai 2026, 16:20 UTC

Market Talk

Ergebnisse

Basic Materials Roundup: Market Talk

25. Mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25. Mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25. Mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25. Mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. Mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25. Mai 2026, 12:56 UTC

Market Talk

Ergebnisse

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25. Mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25. Mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. Mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25. Mai 2026, 12:10 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Delivery Hero's Assets Look Strategic -- Market Talk

25. Mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25. Mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25. Mai 2026, 10:05 UTC

Ergebnisse

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25. Mai 2026, 10:04 UTC

Ergebnisse

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25. Mai 2026, 10:03 UTC

Ergebnisse

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25. Mai 2026, 10:02 UTC

Ergebnisse

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25. Mai 2026, 10:01 UTC

Ergebnisse

Tenaga Nasional 1Q Net Up 3.7% on Year

25. Mai 2026, 10:00 UTC

Ergebnisse

Tenaga Nasional 1Q Rev Up 6.6% on Year

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q EPS MYR0.1883

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q Rev MYR17.1B

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q Net MYR1.1B

25. Mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25. Mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25. Mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25. Mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer-Vergleich

Kursveränderung

Aclaris Therapeutics Inc Prognose

Kursziel

By TipRanks

129.65% Vorteil

12-Monats-Prognose

Durchschnitt 10.38 USD 129.65%

Hoch 16 USD

Tief 4 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Aclaris Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Aclaris Therapeutics Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.